Core Viewpoint - The Fujian Provincial Medical Security Bureau has announced the credit rating of two pharmaceutical companies, Beijing Kangrengtang Pharmaceutical Co., Ltd. and Guizhou Sanli Pharmaceutical Co., Ltd., both rated as "general" due to their involvement in commercial bribery cases [1][4]. Company Ratings - Beijing Kangrengtang Pharmaceutical Co., Ltd. was found to have engaged in bribery amounting to 46,000 yuan from 2013 to 2015 to medical institution personnel [2][4]. - Guizhou Sanli Pharmaceutical Co., Ltd. was involved in a bribery case where approximately 120,000 yuan was given to medical institution doctors to promote the prescription of its product, a children's throat spray [2][4]. Rating Criteria - The credit rating is based on the criteria set forth in the "Medical Price and Procurement Credit Rating Discretionary Standards" (2020 version), which states that companies involved in bribery exceeding 10,000 yuan but less than 150,000 yuan are rated as "general" [2][4].

Group 1 - On September 17, Hongri Pharmaceutical experienced a decline of 1.28% with a trading volume of 202 million yuan, and the net financing buy was -7.32 million yuan [1] - As of September 17, the total margin balance for Hongri Pharmaceutical was 646 million yuan, with a financing balance of 645 million yuan, accounting for 5.55% of the circulating market value, which is below the 20th percentile level over the past year [1] - The company’s main business revenue composition includes 57.27% from traditional Chinese medicine formula granules and decoction pieces, 21.73% from Xuebijing injection, and 20.14% from smart supply chain for medical devices [1] Group 2 - As of June 30, the number of shareholders for Hongri Pharmaceutical was 100,800, a decrease of 2.01% from the previous period, while the average circulating shares per person increased by 1.98% to 27,160 shares [2] - For the first half of 2025, Hongri Pharmaceutical reported operating revenue of 2.795 billion yuan, a year-on-year decrease of 6.72%, and a net profit attributable to shareholders of 78.63 million yuan, down 46.95% year-on-year [2] - Since its A-share listing, Hongri Pharmaceutical has distributed a total of 1.116 billion yuan in dividends, with 270 million yuan distributed over the past three years [3]

Core Viewpoint - Hongri Pharmaceutical (300026.SZ) announced the need to pay back taxes and penalties totaling 33.83 million yuan, which will directly impact the net profit attributable to shareholders in 2025 [1] Group 1 - The company and its wholly-owned subsidiary are required to pay back taxes of 25.166 million yuan and late fees of 8.6722 million yuan, totaling 33.8382 million yuan [1] - The total amount has been fully paid and does not involve any administrative penalties [1] - The payment will be recorded in the 2025 financial results, affecting the net profit for that year [1]

Core Viewpoint - Hongri Pharmaceutical (300026.SZ) announced the need to pay back taxes totaling 25.166 million yuan and late fees of 8.6722 million yuan, amounting to a total of 33.8382 million yuan, which has been fully paid as of the announcement date, and this repayment does not involve any administrative penalties [1] Group 1 - The company and its wholly-owned subsidiary are required to repay taxes and late fees totaling 33.8382 million yuan [1] - The total amount includes 25.166 million yuan in taxes and 8.6722 million yuan in late fees [1] - The repayment has been completed as of the date of the announcement [1]

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-050 天津红日药业股份有限公司（以下简称"公司"）及全资孙公司近期对相关 涉税事项开展自查，需要补缴税款及滞纳金合计3,383.82万元，现将相关情况公 告如下： 一、基本情况 经自查，公司及全资孙公司需补缴税款2,516.60万元，滞纳金867.22万元， 合计3,383.82万元。截至本公告披露日，上述税款及滞纳金缴纳完毕，本次补缴 不涉及行政处罚。 二、对公司的影响 根据《企业会计准则第 28 号——会计政策、会计估计变更和差错更正》相 关规定，上述补缴税款及滞纳金事项不属于前期会计差错，不涉及前期财务数据 追溯调整。公司及全资孙公司补缴上述税款及滞纳金将计入 2025 年当期损益， 对公司 2025 年度归属于上市公司股东的净利润的影响，最终以 2025 年度经审计 的财务报表为准。敬请广大投资者注意投资风险。 特此公告。 天津红日药业股份有限公司 天津红日药业股份有限公司 关于补缴税款的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 董 事 会 二○二五 ...

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-049 天津红日药业股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1．本次股东大会无增加、变更、否决提案的情况； 2．本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开和出席情况 天津红日药业股份有限公司（以下简称"公司"）董事会于2025年08月28日 以公告方式向全体股东发出召开2025年第二次临时股东大会的通知。本次股东大 会采取现场投票和网络投票相结合的方式召开。其中，现场会议于2025年09月16 日下午14:30在天津市武清开发区创业总部基地B01号楼公司会议室召开；通过深 圳证券交易所系统进行网络投票的时间为2025年09月16日上午09:15至09:25、 09:30-11:30，下午13:00-15:00；通过深圳证券交易所互联网投票系统投票的具 体时间为2025年09月16日09:15至2025年09月16日15:00的任意时间。 出席本次会议的股东及股东代表共 725 ...

北京市康达律师事务所 关于天津红日药业股份有限公司 北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 2025 年第二次临时股东大会的法律意见书 康达股会字【2025】第 0397 号 致：天津红日药业股份有限公司 北京市康达律师事务所（以下简称"本所"）接受天津红日药业股份有限 公司（以下简称"公司"）的委托，指派本所律师参加公司 2025 年第二次临时 股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券 ...

Core Viewpoint - The event highlighted the importance of rigorous processes and assessment mechanisms in selecting and managing research partners for drug development [1] Group 1: Company Overview - Hongri Pharmaceutical's president, Lan Wujun, emphasized the company's commitment to scientific and data-driven approaches in developing modern traditional Chinese medicine products [1] - The company aims to develop safe, effective, and high-quality products while adhering to relevant regulations and project progress [1] Group 2: Research and Development - The complexity and professionalism of drug development were acknowledged, with an emphasis on understanding the progress of specific product applications [1] - The company plans to disclose significant advancements to investors through legal information channels at appropriate times [1]

Core Viewpoint - The company aims to enhance profitability and ensure stable development by improving cost efficiency and leveraging its internal capabilities through a comprehensive approach across the entire industry chain [1] Group 1 - The company plans to strengthen the coordination of research, production, and sales [1] - The focus will be on stimulating internal motivation and exploring its potential [1] - The ultimate goal is to maximize profits and lay a solid foundation for steady growth [1]

Core Viewpoint - Tianjin Hongri Pharmaceutical Co., Ltd. held an investor meeting on September 11, 2025, to discuss its semi-annual performance and governance, engaging with investors on various topics [1] Group 1: R&D and Strategy - Investors inquired about the increase in R&D investment in innovative chemical and biological drugs for the first half of 2025, as well as the company's differentiation strategy regarding PD-1/L1 target research [2] - The company emphasized that R&D innovation is a core strategy, acknowledging the lengthy and uncertain nature of new drug development [2] - There were concerns about the company's dual-driven strategy being mere rhetoric, to which the company responded that it is based on concrete actions and long-term planning [2] Group 2: Business Operations and Management - Investors raised questions about the progress and profitability of the collaboration with Chengdu Medical Investment on the Rongcheng Elderly Care Project, with the company advising to refer to periodic reports for updates [2] - Suggestions were made for the company to adopt promotional strategies for its "Shangyimingjia" internet platform, which the company acknowledged [2] - The management's professional background was questioned due to performance declines post the acquisition by Xingcheng Group, with the company asserting compliance with legal and regulatory standards in management appointments [2] Group 3: Financial Performance and Market Management - The company addressed inquiries regarding sales, management appointments, product sales, and R&D progress, stating that it would evaluate single products for policy support to ensure overall effectiveness [2] - On market capitalization management, the company noted that stock prices are influenced by various factors and has established a market value management system to enhance operational efficiency [2] - The company confirmed no significant changes in revenue contribution from various business segments and has no current acquisition plans [2]